Myelofibrosis Treatment Market Statistics for Upcoming Industry Size, Share Value, Including High Volume Players like Novartis, Eli Lilly, Roche, Merck & Co., Celgene, Amgen, Bristol-Myers Squibb, Incyte Corporation

Overview:

Myelofibrosis is a rare blood cancer, in which fibrous scar tissue replace bone marrow. Myelofibrosis is considered as a form of lukemia. The symptoms of the disease comprise fatigue, anemia, enlarged spleen and weakness. Myelofibrosis is often observed in people over the age of 50 years. It is categorised into primary and secondary myelofibrosis. Treatment options for the disease are rare. However, in 2011, the U.S. FDA grated approval to Jakafi (Ruxolitinib), the only product approved by FDA for myelofibrosis treatment.

Request For FREE Sample Copy 

Drivers:

Frequent FDA approvals of pipeline drugs, large investment in R&D, large number of patients with myelofibrosis, favourable reimbursement policies are expected to boost growth of the global myelofibrosis treatment market.

Increasing development in myelofibrosis treatment is also expected to propel growth of the global myelofibrosis treatment market. For instance, Gilead Sciences developed CYT387 or Momelotinib, for treatment of primary myelofibrosis. Similarly, Incyte Corporation developed a current drug, ruxolitinib, a substitute dosing strategy for myelofibrosis patients.

Moreover, factors such as change in lifestyle, growing cases of genetic disorders, and rising population with smoking habits are expected to propel growth of the myelofibrosis treatment market.

Restraints:

High cost of treatment and lack of awareness of new therapies are expected to hamper growth of the global myelofibrosis treatment market.

Market Taxonomy:

The global myelofibrosis treatment market is divided into diagnosis, treatment, end user, and geography.

By diagnosis:

• Gene Mutation Analysis

• Bone Marrow Biopsy

• Imaging Tests

• Blood Tests

By treatment:

• Chemotherapy

• Blood Transfusions

• Stem Cell Transplant

• Splenectomy

• Radiation Therapy

• Others

By end user:               

• Hospitals

• Clinics

• Bone Marrow Transplant Centers

Regional analysis:

The global myelofibrosis treatment market is regionally divided into North America, Europe, Latin America, Middle East, Asia Pacific, and Africa.

Request Here For PDF Brochure 

North America is expected to witness substantial growth in the global myelofibrosis treatment market due to increasing cases of diseases, rising awareness, encouraging reimbursement policies, and high expenditure in healthcare. In 2016, the American Society of Hematology reported around 20,000 Americans are affected by myelofibrosis, which is a highly fatal blood cancer.

Asia Pacific is expected to witness significant growth in the global market of myelofibrosis treatment, attributed to increasing geriatric population, growing disposable incomes and advanced healthcare facilities.

Major players:

Major players active in the global myelofibrosis treatment market are Eli Lilly, Merck & Co., Celgene, Bristol-Myers Squibb, Gilead Sciences, Novartis, Roche, Amgen, and Incyte Corporation.

Buy ThisPremium Report 

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Myelofibrosis Treatment Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Myelofibrosis Treatment Industry Impact

Chapter 2 Global Myelofibrosis Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Myelofibrosis Treatment (Volume and Value) by Type
2.3 Global Myelofibrosis Treatment (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Myelofibrosis Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Myelofibrosis Treatment Market Analysis
Chapter 6 East Asia Myelofibrosis Treatment Market Analysis
Chapter 7 Europe Myelofibrosis Treatment Market Analysis
Chapter 8 South Asia Myelofibrosis Treatment Market Analysis
Chapter 9 Southeast Asia Myelofibrosis Treatment Market Analysis
Chapter 10 Middle East Myelofibrosis Treatment Market Analysis
Chapter 11 Africa Myelofibrosis Treatment Market Analysis
Chapter 12 Oceania Myelofibrosis Treatment Market Analysis
Chapter 13 South America Myelofibrosis Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Myelofibrosis Treatment Business
Chapter 15 Global Myelofibrosis Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology